Barclays PLC Buys 46,370 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Barclays PLC increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 146.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,021 shares of the biopharmaceutical company’s stock after buying an additional 46,370 shares during the quarter. Barclays PLC owned 0.16% of Puma Biotechnology worth $199,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of PBYI. SG Americas Securities LLC bought a new position in shares of Puma Biotechnology during the 3rd quarter worth approximately $34,000. Dynamic Technology Lab Private Ltd acquired a new position in Puma Biotechnology in the third quarter valued at about $44,000. Patriot Financial Group Insurance Agency LLC boosted its position in Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares in the last quarter. Royce & Associates LP grew its stake in Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 8,427 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in shares of Puma Biotechnology during the second quarter worth approximately $54,000. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Up 20.3 %

Shares of NASDAQ PBYI opened at $3.55 on Tuesday. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73. The firm’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $2.98. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company has a market cap of $174.26 million, a price-to-earnings ratio of 7.40 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the business earned $0.12 earnings per share. On average, research analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now owns 7,029,674 shares in the company, valued at $22,143,473.10. The trade was a 0.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the sale, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 23.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.